Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030484 | 0.90 | MAPT (0.48) | MAPTSIRT2SIRT1SIRT3POLB | |
| SCHEMBL6030202 | 0.90 | MAPT (0.50) | MAPTSIRT2SIRT1SIRT3POLB | |
| SCHEMBL6030298 | 0.84 | MAPT (0.46) | MAPTPOLBALDH1A1HPGDTSHR | |
| SCHEMBL6029258 | 0.83 | MAPT (0.47) | MAPTPOLBALDH1A1HPGDTSHR | |
| SCHEMBL6029726 | 0.82 | MAPT (0.48) | MAPTPOLBALDH1A1TP53HPGD | |
| SCHEMBL3490918 | 0.82 | ALDH1A1 (0.59) | MAPTPOLBALDH1A1HPGDTSHR | |
| SCHEMBL6029684 | 0.80 | MAPT (0.45) | MAPTSIRT2SIRT1SIRT3POLB | |
| SCHEMBL6031521 | 0.80 | MAPT (0.45) | MAPTSIRT2SIRT1SIRT3POLB | |
| SCHEMBL6031142 | 0.80 | MAPT (0.45) | MAPTSIRT2SIRT1SIRT3POLB | |
| SCHEMBL6030356 | 0.80 | MAPT (0.45) | MAPTSIRT2SIRT1SIRT3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064122-B2 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1467978-A4 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1467978-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003053944-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | PNLIP, LIPC, CEL | MAPT 4105/4885SIRT2 4163/4885SIRT1 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.